Analysis of the relationship between expression of caveolin-1 and prognosis in bladder transitional cell carcinoma.
- Author:
Jiang RUAN
1
;
Zhi-Liang WENG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; metabolism; pathology; surgery; Caveolin 1; metabolism; Cystectomy; methods; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; metabolism; pathology; Risk Factors; Survival Rate; Urinary Bladder Neoplasms; metabolism; pathology; surgery
- From: Chinese Journal of Oncology 2010;32(6):429-431
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyze the relationship between expressions of caveolin-1 and prognosis in bladder transitional cell carcinoma (BTCC).
METHODSThe expression of caveolin-1 was detected in 85 cases of BTCC. 64 cases of primary BTCC were followed-up after operation. The tumor-free survival time in recurrent BTCC patients was observed.
RESULTSThe positive expression rates of caveolin-1 in primary and recurrent BTCC were 32.8% and 61.9%, respectively, with a significant difference (P < 0.05). There was a significant difference (P < 0.05) between the tumor-free survival times in the groups with positive and negative expressions of caveolin-1. The half-, 1-, 2- and 3-year tumor-free survival rates in the group with positive expression of caveolin-1 were 90.4%, 80.9%, 66.3% and 56.1%, respectively. The half-, 1-, 2-, and 3-year tumor-free survival rates in the group with negative expression of caveolin-1 were 97.7%, 95.4%, 81.4% and 79.0%, respectively. The tumor-free survival rate in the group with positive expression of caveolin-1 was significantly lower than that in the group with negative expression of caveolin-1 (P < 0.05).
CONCLUSIONPositive expression of caveolin-1 in BTCC can be regarded as a high risk factor of recurrence of BTCC. Positive expression of caveolin-1 in BTCC is correlated with the prognosis of BTCC, and BTCC patients with positive expression of caveolin-1 should be followed-up after operation.
